The physiology of cardiovascular disease and innovative liposomal platforms for therapy

Ruiz–Esparza, Guillermo U.; Flores‐Arredondo, Jose H.; Segura‐Ibarra, Victor; Torre‐Amione, Guillermo; Ferrari, Mauro; Blanco, Elvin; Serda, Rita E.

doi:10.2147/ijn.s30599

Cited by 22 publications

(18 citation statements)

References 108 publications

(91 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The in vivo cell tracking by MRI clearly showed that administered cells were preferentially located surrounding the left ventricle. These results are relevant because myocardial infarction frequently involves the left ventricle [ 34 ], so this route may initially provide an optimal cell location and retention rate in the region of interest. Interestingly, previous results from our group, using intramyocardial delivery in the same animal model under similar conditions [ 35 ], showed that cell distribution and retention is comparable to that by intrapericardial administration.…”

Section: Discussionmentioning

confidence: 99%

Intrapericardial Administration of Mesenchymal Stem Cells in a Large Animal Model: A Bio-Distribution Analysis

et al. 2015

View full text Add to dashboard Cite

The appropriate administration route for cardiovascular cell therapy is essential to ensure the viability, proliferative potential, homing capacity and implantation of transferred cells. At the present, the intrapericardial administration of pharmacological agents is considered an efficient method for the treatment of cardiovascular diseases. However, only a few reports have addressed the question whether the intrapericardial delivery of Mesenchymal Stem Cells (MSCs) could be an optimal administration route. This work firstly aimed to analyze the pericardial fluid as a cell-delivery vehicle. Moreover, the in vivo biodistribution pattern of intrapericardially administered MSCs was evaluated in a clinically relevant large animal model. Our in vitro results firstly showed that, MSCs viability, proliferative behavior and phenotypic profile were unaffected by exposure to pericardial fluid. Secondly, in vivo cell tracking by magnetic resonance imaging, histological examination and Y-chromosome amplification clearly demonstrated the presence of MSCs in pericardium, ventricles (left and right) and atrium (left and right) when MSCs were administered into the pericardial space. In conclusion, here we demonstrate that pericardial fluid is a suitable vehicle for MSCs and intrapericardial route provides an optimal retention and implantation of MSCs.

show abstract

Section: Discussionmentioning

confidence: 99%

Intrapericardial Administration of Mesenchymal Stem Cells in a Large Animal Model: A Bio-Distribution Analysis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…This study also confirms the active or passive targeting of liposomal platforms in the murine model of AMI within a week compared to the non-targeted liposomes. 157 A study combining micellar and liposomal nanoformulations for treating AMI suggests liposomes and micelles as proangiogenic and cardioprotective drug delivery systems. 158 Liposomes containing prednisone has used for the treatment of patients with atherosclerotic plaques.…”

Section: Liposomal Platformsmentioning

confidence: 99%

<p>Nanoparticle-Mediated Drug Delivery for the Treatment of Cardiovascular Diseases</p>

Pala

Anju

Dyavaiah

et al. 2020

IJN

113

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) are one of the foremost causes of high morbidity and mortality globally. Preventive, diagnostic, and treatment measures available for CVDs are not very useful, which demands promising alternative methods. Nanoscience and nanotechnology open a new window in the area of CVDs with an opportunity to achieve effective treatment, better prognosis, and less adverse effects on non-target tissues. The application of nanoparticles and nanocarriers in the area of cardiology has gathered much attention due to the properties such as passive and active targeting to the cardiac tissues, improved target specificity, and sensitivity. It has reported that more than 50% of CVDs can be treated effectively through the use of nanotechnology. The main goal of this review is to explore the recent advancements in nanoparticle-based cardiovascular drug carriers. This review also summarizes the difficulties associated with the conventional treatment modalities in comparison to the nanomedicine for CVDs.

show abstract

“…The need for targeting drugs for cardiovascular disease has become very critical [72]. Several drugs used for cardiovascular diseases have been subjected to FDA withdrawals [73].…”

Section: Organ-on-a-chip Platforms As a Potential Solutionmentioning

confidence: 99%

Organ-on-a-chip platforms for studying drug delivery systems

Bhise

Ribas

Manoharan

et al. 2014

Journal of Controlled Release

322

242

View full text Add to dashboard Cite

Novel microfluidic tools allow new ways to manufacture and test drug delivery systems. Organ-on-a-chip systems – microscale recapitulations of complex organ functions – promise to improve the drug development pipeline. This review highlights the importance of integrating microfluidic networks with 3D tissue engineered models to create organ-on-a-chip platforms, able to meet the demand of creating robust preclinical screening models. Specific examples are cited to demonstrate the use of these systems for studying the performance of drug delivery vectors and thereby reduce the discrepancies between their performance at preclinical and clinical trials. We also highlight the future directions that need to be pursued by the research community for these proof-of-concept studies to achieve the goal of accelerating clinical translation of drug delivery nanoparticles.

show abstract

The physiology of cardiovascular disease and innovative liposomal platforms for therapy

Cited by 22 publications

References 108 publications

Intrapericardial Administration of Mesenchymal Stem Cells in a Large Animal Model: A Bio-Distribution Analysis

Intrapericardial Administration of Mesenchymal Stem Cells in a Large Animal Model: A Bio-Distribution Analysis

<p>Nanoparticle-Mediated Drug Delivery for the Treatment of Cardiovascular Diseases</p>

Organ-on-a-chip platforms for studying drug delivery systems

Contact Info

Product

Resources

About